These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21118740)

  • 1. Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk.
    Sekijima Y; Ohashi T; Ohira S; Kosho T; Fukushima Y
    Clin Ther; 2010 Nov; 32(12):2048-52. PubMed ID: 21118740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breastfeeding in Gaucher disease: is enzyme replacement therapy safe?
    Dornelles AD; de Oliveira Netto CB; Vairo F; de Mari JF; Tirelli KM; Schwartz IV
    Clin Ther; 2014 Jun; 36(6):990-1. PubMed ID: 24768190
    [No Abstract]   [Full Text] [Related]  

  • 3. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
    Zimran A; Morris E; Mengel E; Kaplan P; Belmatoug N; Hughes DA; Malinova V; Heitner R; Sobreira E; Mrsić M; Granovsky-Grisaru S; Amato D; vom Dahl S
    Blood Cells Mol Dis; 2009; 43(3):264-88. PubMed ID: 19502088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.
    Berger J; Vigan M; Pereira B; Nguyen TT; Froissart R; Belmatoug N; Dalbiès F; Masseau A; Rose C; Serratrice C; Pers YM; Bertchansky I; Camou F; Bengherbia M; Bourgne C; Caillaud C; Pettazzoni M; Berrahal A; Stirnemann J; Mentré F; Berger MG
    Clin Pharmacokinet; 2019 Apr; 58(4):469-482. PubMed ID: 30128966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R; Arndt S; Levin JB
    S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful desensitization to imiglucerase of an adult patient diagnosed with type I Gaucher disease.
    Erdoğdu D; Gelincik A; Canbaz B; Colakoğlu B; Büyüköztürk S; Tanakol R
    Int Arch Allergy Immunol; 2013; 160(2):215-7. PubMed ID: 23018845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy with imiglucerase in a Taiwanese child with type 1 Gaucher disease.
    Lin HY; Lin SP; Chuang CK; Wraith JE
    J Chin Med Assoc; 2006 May; 69(5):228-32. PubMed ID: 16835986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
    Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of Gaucher disease in developing countries: a successful experience in Southern Brazil.
    Krug BC; Schwartz IV; Lopes de Oliveira F; Alegra T; Campos Martins NL; Todeschini LA; Picon PD
    Public Health Genomics; 2010; 13(1):27-33. PubMed ID: 19407439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
    Kishnani PS; DiRocco M; Kaplan P; Mehta A; Pastores GM; Smith SE; Puga AC; Lemay RM; Weinreb NJ
    Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
    Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
    Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24months.
    Ida H; Tanaka A; Matsubayashi T; Murayama K; Hongo T; Lee HM; Mellgard B
    Blood Cells Mol Dis; 2016 Jul; 59():140-7. PubMed ID: 27241455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
    Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
    Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
    Cox TM; Drelichman G; Cravo R; Balwani M; Burrow TA; Martins AM; Lukina E; Rosenbloom B; Ross L; Angell J; Puga AC
    Lancet; 2015 Jun; 385(9985):2355-62. PubMed ID: 25819691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
    J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.